دورية أكاديمية
Plasma S100beta is not a useful biomarker for tumor burden in neurofibromatosis
| العنوان: | Plasma S100beta is not a useful biomarker for tumor burden in neurofibromatosis |
|---|---|
| المؤلفون: | Smith, M J, Esparza, S, Merker, V L, Muzikansky, A, Bredella, M A, Harris, G J, Kassarjian, A, Cai, W, Walker, J A, Mautner, V F, Plotkin, S R |
| المصدر: | Smith , M J , Esparza , S , Merker , V L , Muzikansky , A , Bredella , M A , Harris , G J , Kassarjian , A , Cai , W , Walker , J A , Mautner , V F & Plotkin , S R 2013 , ' Plasma S100beta is not a useful biomarker for tumor burden in neurofibromatosis ' , Clin Biochem , vol. 46 , no. 7-8 , pp. 698-700 . https://doi.org/S0009-9120Test(12)00695-9 [pii] 10.1016/j.clinbiochem.2012.12.007 |
| سنة النشر: | 2013 |
| المجموعة: | The University of Manchester: Research Explorer - Publications |
| مصطلحات موضوعية: | Adult, Female, Humans, Male, Middle Aged, Nerve Growth Factors/*blood, Neurofibromatoses/diagnosis/*pathology, Neurofibromatosis 1/pathology, Neurofibromatosis 2/pathology, Neuroma, Acoustic/pathology, S100 Calcium Binding Protein beta Subunit, S100 Proteins/*blood, Tumor Burden |
| الوصف: | OBJECTIVES: Neurofibromatosis 1 (NF1), NF2, and schwannomatosis are characterized by a predisposition to develop multiple neurofibromas and schwannomas. Currently, there is no blood test to estimate tumor burden in patients with these disorders. We explored whether S100beta would act as a biomarker of tumor burden in NF since S100beta is a classic immunohistochemical marker of astrocytes, oligodendrocytes and Schwann cells and a small study showed S100beta concentrations correlate with the volume of vestibular schwannomas. DESIGN AND METHODS: We calculated whole-body tumor burden in subjects with NF1, NF2, and schwannomatosis using whole-body MRI (WBMRI) and measured the concentration of S100beta in plasma using ELISA. We used chi-square tests and Spearman rank correlations to test the relationship between S100beta levels and whole-body tumor burden. RESULTS: 127 consecutive patients were enrolled in the study (69 NF1 patients, 28 NF2 patients, and 30 schwannomatosis patients). The median age was 40years, 43% were male, and median whole-body tumor volume was 26.9mL. There was no relationship between the presence of internal tumors and the presence of detectable S100beta in blood for the overall group or for individual diagnoses (p>0.05 by chi-square for all comparisons). Similarly, there was no correlation between whole-body tumor volume and S100beta concentration for the overall group or for individual diagnoses (p>0.05 by Spearman for all comparisons). CONCLUSIONS: Plasma S100beta is not a useful biomarker for tumor burden in the neurofibromatoses. Further work is needed to identify a reliable biomarker of tumor burden in NF patients. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.clinbiochem.2012.12.007 |
| الإتاحة: | https://doi.org/10.1016/j.clinbiochem.2012.12.007Test https://research.manchester.ac.uk/en/publications/ea766663-61f4-4290-81fa-893320f42866Test http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23261835Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.BB2FB7CD |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.clinbiochem.2012.12.007 |
|---|